Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Trial Profile

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs ACTR707 (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 04 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 21 Jun 2017 New trial record
    • 19 Jun 2017 According to an Unum Therapeutics media release, an investigational new drug (IND) application for ACTR707 in combination with rituximab for the treatment of adult patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma, is now active. Site initiation activities are currently underway and the company anticipates that enrollment will begin in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top